Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by ProShare Advisors LLC

ProShare Advisors LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 146,135 shares of the biopharmaceutical company’s stock after purchasing an additional 26,018 shares during the period. ProShare Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $104,096,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Fifth Third Wealth Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 118.1% in the fourth quarter. Fifth Third Wealth Advisors LLC now owns 1,099 shares of the biopharmaceutical company’s stock valued at $783,000 after buying an additional 595 shares in the last quarter. Park Avenue Securities LLC increased its holdings in Regeneron Pharmaceuticals by 6.9% in the fourth quarter. Park Avenue Securities LLC now owns 2,019 shares of the biopharmaceutical company’s stock valued at $1,438,000 after buying an additional 130 shares in the last quarter. Outlook Wealth Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $305,000. Hennion & Walsh Asset Management Inc. increased its holdings in Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 3,106 shares of the biopharmaceutical company’s stock valued at $2,212,000 after buying an additional 99 shares in the last quarter. Finally, Fermata Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $207,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 2.4%

Shares of REGN opened at $584.99 on Friday. The firm has a market cap of $63.95 billion, a PE ratio of 15.28, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The company’s fifty day moving average is $602.44 and its two-hundred day moving average is $686.93. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $520.50 and a fifty-two week high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter last year, the business earned $9.55 EPS. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.60%. Regeneron Pharmaceuticals’s payout ratio is 8.96%.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on REGN shares. Bernstein Bank dropped their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Robert W. Baird dropped their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating for the company in a research note on Friday, April 25th. TD Cowen dropped their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. Finally, The Goldman Sachs Group dropped their price objective on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $890.60.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.